These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24884602)

  • 21. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
    Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
    Sinclair A; Bode B; Harris S; Vijapurkar U; Mayer C; Fung A; Shaw W; Usiskin K; Desai M; Meininger G
    BMC Endocr Disord; 2014 Apr; 14():37. PubMed ID: 24742013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Interleukin-1β Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial.
    Vallurupalli M; MacFadyen JG; Glynn RJ; Thuren T; Libby P; Berliner N; Ridker PM
    Ann Intern Med; 2020 Apr; 172(8):523-532. PubMed ID: 32203978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
    Ruperto N; Brunner HI; Quartier P; Constantin T; Wulffraat N; Horneff G; Brik R; McCann L; Kasapcopur O; Rutkowska-Sak L; Schneider R; Berkun Y; Calvo I; Erguven M; Goffin L; Hofer M; Kallinich T; Oliveira SK; Uziel Y; Viola S; Nistala K; Wouters C; Cimaz R; Ferrandiz MA; Flato B; Gamir ML; Kone-Paut I; Grom A; Magnusson B; Ozen S; Sztajnbok F; Lheritier K; Abrams K; Kim D; Martini A; Lovell DJ; ;
    N Engl J Med; 2012 Dec; 367(25):2396-406. PubMed ID: 23252526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement : Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial.
    Schieker M; Conaghan PG; Mindeholm L; Praestgaard J; Solomon DH; Scotti C; Gram H; Thuren T; Roubenoff R; Ridker PM
    Ann Intern Med; 2020 Oct; 173(7):509-515. PubMed ID: 32744862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies.
    Angiolillo DJ; Datto C; Raines S; Yeomans ND
    J Thromb Thrombolysis; 2014 Jul; 38(1):11-23. PubMed ID: 24368727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
    Fioretto P; Mansfield TA; Ptaszynska A; Yavin Y; Johnsson E; Parikh S
    Drugs Aging; 2016 Jul; 33(7):511-22. PubMed ID: 27357173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies.
    Schweizer A; Dejager S; Foley JE; Kothny W
    Vasc Health Risk Manag; 2011; 7():49-57. PubMed ID: 21415917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
    Kuemmerle-Deschner JB; Hachulla E; Cartwright R; Hawkins PN; Tran TA; Bader-Meunier B; Hoyer J; Gattorno M; Gul A; Smith J; Leslie KS; Jiménez S; Morell-Dubois S; Davis N; Patel N; Widmer A; Preiss R; Lachmann HJ
    Ann Rheum Dis; 2011 Dec; 70(12):2095-102. PubMed ID: 21859692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.
    Kohler S; Zeller C; Iliev H; Kaspers S
    Adv Ther; 2017 Jul; 34(7):1707-1726. PubMed ID: 28631216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
    Kohler S; Salsali A; Hantel S; Kaspers S; Woerle HJ; Kim G; Broedl UC
    Clin Ther; 2016 Jun; 38(6):1299-1313. PubMed ID: 27085585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
    Ridker PM; MacFadyen JG; Everett BM; Libby P; Thuren T; Glynn RJ;
    Lancet; 2018 Jan; 391(10118):319-328. PubMed ID: 29146124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canakinumab: in patients with cryopyrin-associated periodic syndromes.
    Curran MP
    BioDrugs; 2012 Feb; 26(1):53-9. PubMed ID: 22168385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.
    Koné-Paut I; Lachmann HJ; Kuemmerle-Deschner JB; Hachulla E; Leslie KS; Mouy R; Ferreira A; Lheritier K; Patel N; Preiss R; Hawkins PN;
    Arthritis Res Ther; 2011; 13(6):R202. PubMed ID: 22152723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.
    Davies MJ; Merton K; Vijapurkar U; Yee J; Qiu R
    Cardiovasc Diabetol; 2017 Mar; 16(1):40. PubMed ID: 28327140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.
    Qiu R; Balis D; Xie J; Davies MJ; Desai M; Meininger G
    Curr Med Res Opin; 2017 Mar; 33(3):553-562. PubMed ID: 27977934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
    Ridker PM; MacFadyen JG; Thuren T; Libby P
    Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis.
    Chakraborty A; Van LM; Skerjanec A; Floch D; Klein UR; Krammer G; Sunkara G; Howard D
    J Clin Pharmacol; 2013 Dec; 53(12):1240-51. PubMed ID: 24122883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.
    Behrens F; Tak PP; Østergaard M; Stoilov R; Wiland P; Huizinga TW; Berenfus VY; Vladeva S; Rech J; Rubbert-Roth A; Korkosz M; Rekalov D; Zupanets IA; Ejbjerg BJ; Geiseler J; Fresenius J; Korolkiewicz RP; Schottelius AJ; Burkhardt H
    Ann Rheum Dis; 2015 Jun; 74(6):1058-64. PubMed ID: 24534756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.